Artificial intelligence for high content imaging in drug discovery
Evidence
Curr Opin Struct Biol. 2024 May 25;87:102842. doi: 10.1016/j.sbi.2024.102842. Online ahead of print.
ABSTRACT
Artificial intelligence (AI) and high-content imaging (HCI) are contributing to advancements in drug discovery, propelled by the recent progress in deep neural networks. This review highlights AI’s role in analysis of HCI data from fixed and live-cell imaging, enabling novel label-free and multi-channel fluorescent screening methods, and improving compound profiling. HCI experiments are rapid and cost-effective, facilitating large data set accumulation for AI model training. However, the success of AI in drug discovery also depends on high-quality data, reproducible experiments, and robust validation to ensure model performance. Despite challenges like the need for annotated compounds and managing vast image data, AI’s potential in phenotypic screening and drug profiling is significant. Future improvements in AI, including increased interpretability and integration of multiple modalities, are expected to solidify AI and HCI’s role in drug discovery.
J Pharm Bioallied Sci. 2024 Apr;16(Suppl 2):S1136-S1139. doi: 10.4103/jpbs.jpbs_1287_23. Epub 2024 Apr 16.ABSTRACTBACKGROUND: AI in healthcare services is advancing every day, with a focus on...
J Pharm Bioallied Sci. 2024 Apr;16(Suppl 2):S1815-S1820. doi: 10.4103/jpbs.jpbs_1162_23. Epub 2024 Apr 16.ABSTRACTBACKGROUND: Mounting research suggests that artificial intelligence (AI) is one of the innovations...
J Pharm Bioallied Sci. 2024 Apr;16(Suppl 2):S1481-S1486. doi: 10.4103/jpbs.jpbs_1019_23. Epub 2024 Apr 16.ABSTRACTArtificial intelligence (AI) is an emerging tool in modern medicine and the digital...
Front Med (Lausanne). 2024 May 2;11:1380940. doi: 10.3389/fmed.2024.1380940. eCollection 2024.ABSTRACTEmerging digital technologies promise to improve breast cancer care, however lack of awareness among clinicians often...
Biochem Med (Zagreb). 2024 Jun 15;34(2):020707. doi: 10.11613/BM.2024.020707.ABSTRACTINTRODUCTION: We compared the quality control efficiency of artificial intelligence-patient-based real-time quality control (AI-PBRTQC) and traditional PBRTQC in...
Eye Vis (Lond). 2024 Jun 17;11(1):23. doi: 10.1186/s40662-024-00389-y.ABSTRACTBACKGROUND: Diabetic retinopathy (DR) and diabetic macular edema (DME) are major causes of visual impairment that challenge global...
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.